TGFB1 and pancreatic neoplasm: In pancreatic tumors, TAMs exhibit both M1 and M2 phenotypes, but show preferential expression of M2 markers such as Arginase 1, CD206, and TGF-β leading to a higher M2:M1 ratios which correlates with a poorer prognosis in pancreatic cancer patients21,22.